Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction?
Author(s): Van Gaal LF, Wauters MA, Peiffer FW, De Leeuw IH Affiliation(s): Department of Endocrinology, Metabolism & Clinical Nutrition, Faculty of Medicine, University Hospital Antwerp, University of Antwerp, Belgium. Publication date & source: 1998-08, Int J Obes Relat Metab Disord., 22 Suppl 1:S38-40 Publication type: Clinical Trial; Randomized Controlled Trial Visceral adiposity has a strong and independent association with obesity and its related co-morbidities, particularly metabolic complications such as cardiovascular disease and type II diabetes. Waist circumference and waist-to-hip ratio (WHR) are both secondary indicators of visceral obesity. This paper examines the effect of sibutramine, a new serotonin and noradrenaline re-uptake inhibitor, on weight reduction and changes in fat distribution. A meta-analysis of four long-term, placebo-controlled, double-blind studies showed significantly greater mean decreases in waist circumference in sibutramine-treated subjects compare
